Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
A Prospective Study to Evaluate Optimal Margin of Iterative Cone-beam Computed Tomography Guided Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Fuquan Zhang, M.D.
- Phone Number: +86 13311360431
- Email: zhangfq@pumch.cn
Study Contact Backup
- Name: Guangyu Wang, M.D.
- Phone Number: +86 19862181605
- Email: sdwanggy@sina.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100730
- Peking Union Medical College Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must be informed of the investigational nature of this study and give written informed consent before treatment.
- Postoperative endometrial and cervical cancer patients with pathologically confirmed no residual tumor at the resection margin and no evidence of distant metastasis (FIGO stage IVB).
- Pathological findings indicate risk factors and adjuvant radiotherapy are prescribe.
- Karnofsky score ≥ 70.
- Subjects aged ≥ 18 years and ≤ 70 years.
- No evidence of para-aortic metastatic lymph nodes.
- No contraindications to CT scanning.
- Subjects must be able to cooperate in completing the entire study.
- Adequate marrow: neutrophile granulocyte count ≥1.5*10^9/L, hemoglobin ≥ 80 g/L, platelet count ≥100*10^9/L.
- Normal liver and kidney function: Creatinine (Cr) < 1.5 mg/dl, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) < 2*upper limit of normal (ULN).
Exclusion Criteria:
- Subjects who have received prior pelvic radiotherapy.
- Subjects with other primary malignancies.
- Subjects with contraindications to radiotherapy, as determined by the investigators.
- Any severe disease which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control, and emotional disturbance.
- Active infection with fever.
- Active inflammatory bowel disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Online Adaptive Radiotherapy
Patients receive online adaptive radiotherapy.
The CTV contours of the following areas: vaginal cuff, obturator nodal chain, internal iliac nodal chain, external iliac nodal chain, presacral nodal chain and common iliac nodal chain.
The upper border of CTV is at the level of aortic bifurcation.
A dose of 45-50.4Gy is delivered to CTV with online adaptive radiotherapy.
|
CTV covers pelvis.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The dose coverage of target volume as assessed by planing tumor volume V100%
Time Frame: Through study completion, total an average of six month
|
Planing tumor volume V100%, defined as the planing tumor volume receiving at least 100% of the prescribed dose (V100%), is used to evaluate the dose coverage of target volume.
|
Through study completion, total an average of six month
|
|
A minimum PTV margin could encompass CTV
Time Frame: Through study completion, toral an average of six month
|
Expansions were applied to the pretreatment PTV to assess required minimum margin required to encompass the postreatment CTV.
|
Through study completion, toral an average of six month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with acute toxicity as assessed by CTCAE 5.0
Time Frame: From the start of treatment to 3 months after treatment
|
Evaluated with CTCAE 5.0
|
From the start of treatment to 3 months after treatment
|
|
Safety for treatment as assessed by organs at risk doses
Time Frame: Through study completion, total an average of six month
|
Safety for treatment was mainly evaluated by the organs at risk doses, including bladder, rectum, bone marrow, etc
|
Through study completion, total an average of six month
|
|
Adaptive time data
Time Frame: Through study completion, total an average of six month
|
For each treatment in each fraction, adaptive time was recorded from first cone beam computed tomography (CBCT) to the selection of the preferred plan for the treatment.
|
Through study completion, total an average of six month
|
|
Target contouring accuracy
Time Frame: Through study completion, total an average of six month
|
For every target in each fraction, the evaluation of accuracy for target contouring are categorized as follow: no edits, minor edits, moderate edits, major edits and not applicable.
|
Through study completion, total an average of six month
|
|
Organs at risk contouring accuracy
Time Frame: Through study completion, total an average of six month
|
For every organs at risk in each fraction, the evaluation of accuracy for organs at risk contouring are categorized as follows: no edits, minor edits, moderate edits, major edits and not applicable.
|
Through study completion, total an average of six month
|
|
Late toxicity evaluated with Radiation Therapy Oncology Group (RTOG)/EORTC late radiation morbidity scoring scheme
Time Frame: total an average of 2-year
|
Evaluated every three months with Radiation Therapy Oncology Group (RTOG)/EORTC late radiation morbidity scoring scheme
|
total an average of 2-year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Fuquan Zhang, M.D., Peking Union Medical College Hospital
Publications and helpful links
General Publications
- de Jong R, Visser J, van Wieringen N, Wiersma J, Geijsen D, Bel A. Feasibility of Conebeam CT-based online adaptive radiotherapy for neoadjuvant treatment of rectal cancer. Radiat Oncol. 2021 Jul 23;16(1):136. doi: 10.1186/s13014-021-01866-7.
- Schiff JP, Stowe HB, Price A, Laugeman E, Hatscher C, Hugo GD, Badiyan SN, Kim H, Robinson CG, Henke LE. In Silico Trial of Computed Tomography-Guided Stereotactic Adaptive Radiation Therapy (CT-STAR) for the Treatment of Abdominal Oligometastases. Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):1022-1031. doi: 10.1016/j.ijrobp.2022.06.078. Epub 2022 Jun 26.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Uterine Diseases
- Genital Diseases, Female
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Neoplasms
- Uterine Cervical Neoplasms
- Endometrial Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- pumch-ART
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.